This article has been updated from a previous version. Click here for the original article.
It also said that it was planning to sell its facility in
Celera, a unit of Applera, reported a net loss of $5.8 million for Q4 2004 as compared to $19.4 million in Q4 2003. The company said the Q4 results included a $24.8 million pre-tax gain associated with the sale of its investment in Discovery Partners International, as well as an $18.1 million non-cash pre-tax charge representing the estimated loss on the planned
The $18.1 million write-off is due to losses Celera expects to incur after selling the two-building facility in
He also said the company would lease the facility from its new owners, and retain the proteomics and bioinformatics divisions that work there.
Celera's revenues decreased to $12.4 million in Q4 2004, from $21.5 million in the same quarter last year. The company attributed the losses primarily to continuing expiration of online and information business customer agreements.
The company saw a slight rise in its R&D spending in Q4 2004, to $29.4 million, from $28.5 million in Q4 2003. Celera said the rise was primarily to support preclinical development activities and the hiring of additional therapeutic R&D personnel.
As of June 30, Celera's cash and short-term investments totaled approximately $746 million.
Julia Karow contributed to this report.